The impact of an oral nutritional supplement on body weight gain in older adults with malnutrition: an open-label randomized controlled trial.

What Was Tested

This randomized controlled trial looks at Copper (Supplement).

The global aging population is expanding rapidly and many individuals have a particularly higher risk of malnutrition.

Malnutrition can lead to impaired body function, morbidity, and mortality.

Who Took Part

The study group was 50 adults.

By PubMed's age tags, the people studied were older adults.

This is an open-label, randomized controlled, parallel-group study including 50 institutionalized older adults (aged > 60 years) with malnutrition or at risk of malnutrition, living in a selected elderly care institution in Colombo, Sri Lanka.

Older adults will be screened for malnutrition using the Mini Nutrition Assessment (MNA) tool and eligible participants randomized using the simple random sampling technique to intervention and control groups (1:1 allocation ratio).

How the Study Was Run

The design is described as randomized, open-label and parallel-group.

The adults were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

Nothing was hidden in this open-label Copper (Supplement) study: the adults and staff both knew the treatment.

The Copper (Supplement) group and the comparison group ran side by side rather than switching.

Some measurements (anthropometry, dietary, and functional assessments) will also be performed at the end of the 4th week.

Data will be analyzed using SPSS V-23.

What Was Measured

PubMed files the paper under topics including Hand Strength, Quality of Life, Malnutrition, Nutritional Status, Dietary Supplements and Weight Gain.

The authors tagged it with the keywords Body weight, Older adults and Oral nutritional supplementation (ONS).

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Copper (Supplement) in 50 adults.

Results are reported in around 2 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (Trials), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.